ORMP vs. ANRO
ORMP (Oramed Pharmaceuticals Inc.) and ANRO (Alto Neuroscience, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, ORMP returned 101.94% vs 919.11% for ANRO. At a 0.12 correlation, their price movements are largely independent.
Performance
ORMP vs. ANRO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ORMP achieves a 50.93% return, which is significantly higher than ANRO's 28.82% return.
ORMP
- 1D
- 3.35%
- 1M
- 0.50%
- YTD
- 50.93%
- 6M
- 45.32%
- 1Y
- 101.94%
- 3Y*
- 9.79%
- 5Y*
- -21.11%
- 10Y*
- -6.18%
ANRO
- 1D
- 0.84%
- 1M
- 8.06%
- YTD
- 28.82%
- 6M
- 14.42%
- 1Y
- 919.11%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ORMP vs. ANRO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
ORMP Oramed Pharmaceuticals Inc. | 50.93% | 17.77% | -14.49% |
ANRO Alto Neuroscience, Inc | 28.82% | 320.80% | -80.77% |
Correlation
The correlation between ORMP and ANRO is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Feb 2, 2024 | 0.12 |
Fundamentals
ORMP:
$168.30M
ANRO:
$754.24M
ORMP:
$2.86
ANRO:
-$2.50
ORMP:
0.71
ANRO:
3.10
ORMP:
$0.00
ANRO:
$0.00
ORMP:
$0.00
ANRO:
-$421.00K
ORMP:
$67.00M
ANRO:
-$74.36M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ORMP vs. ANRO — Risk / Return Rank
ORMP
ANRO
ORMP vs. ANRO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Oramed Pharmaceuticals Inc. (ORMP) and Alto Neuroscience, Inc (ANRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ORMP | ANRO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -5.23 | ||
| Sortino ratioReturn per unit of downside risk | -2.89 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.72 | -0.38 |
| Calmar ratioReturn relative to maximum drawdown | 4.29 | 27.15 | -22.86 |
| Martin ratioReturn relative to average drawdown | 11.14 | 70.91 | -59.77 |
Loading charts...
Drawdowns
ORMP vs. ANRO - Drawdown Comparison
The maximum ORMP drawdown since its inception was -94.25%, roughly equal to the maximum ANRO drawdown of -91.82%. Use the drawdown chart below to compare losses from any high point for ORMP and ANRO.
Loading charts...
Drawdown Indicators
| ORMP | ANRO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.25% | -91.82% | -2.43% |
Max Drawdown (1Y)Largest decline over 1 year | -23.89% | -34.20% | +10.31% |
Max Drawdown (3Y)Largest decline over 3 years | -52.63% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -94.25% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -94.25% | — | — |
Current DrawdownCurrent decline from peak | -85.54% | -17.28% | -68.26% |
Average DrawdownAverage peak-to-trough decline | -70.78% | -53.30% | -17.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.18% | 13.07% | -3.89% |
Volatility
ORMP vs. ANRO - Volatility Comparison
The current volatility for Oramed Pharmaceuticals Inc. (ORMP) is 15.29%, while Alto Neuroscience, Inc (ANRO) has a volatility of 24.19%. This indicates that ORMP experiences smaller price fluctuations and is considered to be less risky than ANRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ORMP | ANRO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.29% | 24.19% | -8.90% |
Volatility (6M)Calculated over the trailing 6-month period | 39.03% | 54.92% | -15.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 51.51% | 128.77% | -77.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.04% | 115.37% | -34.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.93% | 115.37% | -43.44% |
Dividends
ORMP vs. ANRO - Dividend Comparison
ORMP's dividend yield for the trailing twelve months is around 6.23%, while ANRO has not paid dividends to shareholders.
| Position | TTM |
|---|---|
ANRO Alto Neuroscience, Inc | 0.00% |
ORMP Oramed Pharmaceuticals Inc. | 6.23% |
Financials
ORMP vs. ANRO - Financials Comparison
This section allows you to compare key financial metrics between Oramed Pharmaceuticals Inc. and Alto Neuroscience, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ORMP and ANRO have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ANRO has higher volatility (24.19%) compared to ORMP (15.29%). In terms of maximum drawdown, ORMP dropped -94.25% vs ANRO's -91.82%.
ANRO currently has the higher Sharpe Ratio (7.23 vs 1.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ORMP and ANRO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer